StockMacro
Company, fund or insider

Help

Menu

ANI Pharmaceuticals

$68.55 -16% in 6 monthsMarket cap $1.6B

ANIP on XNAS, Health Care, ANI Pharmaceuticals, Inc., job postings

Measures activity, not value. Not investment advice.

Profit rose 188% to $116.8M and quarterly revenue 28% higher, while shares fell 13% in a year.

  • WatchCapital spending rose 121% to $13.5M in the latest quarter
  • BadInstitutional holders fell 5.3%, from 304 to 288 in a quarter

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.

Industry
Pharmaceutical preparations (Health Care)
Employees
970
Website
anipharmaceuticals.com
Listed
Nasdaq, US
Last results
5 Nov 2026
Next results
expected around 11 Jan 2027 (an estimate: a year ago it reported on 12 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $290.8M, net income $35.1M.
Quarter to 31 Dec 2021: revenue $60.9M, net income -$24.1MQuarter to 31 Dec 2021: revenue $60.9M, net income -$24.1MQuarter to 31 Mar 2022: revenue $64.5M, net income -$20.1MQuarter to 31 Mar 2022: revenue $64.5M, net income -$20.1MQuarter to 30 Jun 2022: revenue $73.9M, net income -$14.9MQuarter to 30 Jun 2022: revenue $73.9M, net income -$14.9MQuarter to 30 Sep 2022: revenue $83.8M, net income -$8.6MQuarter to 30 Sep 2022: revenue $83.8M, net income -$8.6MQuarter to 31 Dec 2022: revenue $94.2M, net income -$4.2MQuarter to 31 Dec 2022: revenue $94.2M, net income -$4.2MQuarter to 31 Mar 2023: revenue $106.8M, net income $1.4MQuarter to 31 Mar 2023: revenue $106.8M, net income $1.4MQuarter to 30 Jun 2023: revenue $116.5M, net income $6.2MQuarter to 30 Jun 2023: revenue $116.5M, net income $6.2MQuarter to 30 Sep 2023: revenue $131.8M, net income $9.9MQuarter to 30 Sep 2023: revenue $131.8M, net income $9.9MQuarter to 31 Dec 2023: revenue $131.7M, net income $1.2MQuarter to 31 Dec 2023: revenue $131.7M, net income $1.2MQuarter to 31 Mar 2024: revenue $137.4M, net income $18.2MQuarter to 31 Mar 2024: revenue $137.4M, net income $18.2MQuarter to 30 Jun 2024: revenue $138.0M, net income -$2.3MQuarter to 30 Jun 2024: revenue $138.0M, net income -$2.3MQuarter to 30 Sep 2024: revenue $148.3M, net income -$24.2MQuarter to 30 Sep 2024: revenue $148.3M, net income -$24.2MQuarter to 31 Dec 2024: revenue $190.6M, net income -$10.3MQuarter to 31 Dec 2024: revenue $190.6M, net income -$10.3MQuarter to 31 Mar 2025: revenue $197.1M, net income $15.7MQuarter to 31 Mar 2025: revenue $197.1M, net income $15.7MQuarter to 30 Jun 2025: revenue $211.4M, net income $8.5MQuarter to 30 Jun 2025: revenue $211.4M, net income $8.5MQuarter to 30 Sep 2025: revenue $227.8M, net income $26.6MQuarter to 30 Sep 2025: revenue $227.8M, net income $26.6MQuarter to 31 Dec 2025: revenue $247.1M, net income $27.5MQuarter to 31 Dec 2025: revenue $247.1M, net income $27.5MQuarter to 31 Mar 2026: revenue $237.5M, net income $29.5MQuarter to 31 Mar 2026: revenue $237.5M, net income $29.5MQuarter to 30 Jun 2026: revenue $266.0M, net income $24.7MQuarter to 30 Jun 2026: revenue $266.0M, net income $24.7MQuarter to 30 Sep 2026: revenue $290.8M, net income $35.1MQuarter to 30 Sep 2026: revenue $290.8M, net income $35.1M
31 Dec 2021RevenueNet incomeNet losstallest bar $290.8M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$290.8M$35.1M
30 Jun 2026$266.0M$24.7M
31 Mar 2026$237.5M$29.5M
31 Dec 2025$247.1M$27.5M
30 Sep 2025$227.8M$26.6M
30 Jun 2025$211.4M$8.5M
31 Mar 2025$197.1M$15.7M
31 Dec 2024$190.6M-$10.3M
30 Sep 2024$148.3M-$24.2M
30 Jun 2024$138.0M-$2.3M
31 Mar 2024$137.4M$18.2M
31 Dec 2023$131.7M$1.2M
30 Sep 2023$131.8M$9.9M
30 Jun 2023$116.5M$6.2M
31 Mar 2023$106.8M$1.4M
31 Dec 2022$94.2M-$4.2M
30 Sep 2022$83.8M-$8.6M
30 Jun 2022$73.9M-$14.9M
31 Mar 2022$64.5M-$20.1M
31 Dec 2021$60.9M-$24.1M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $1.0B $826.9M
Revenue growthRevenue of the last 12 months compared with the 12 months before. +26% +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. $116.8M $40.6M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). $5.01 $1.63
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. 16.0% 8.7% -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. 11.2% 4.9% -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. 20.4% -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. $205.3M $155.7M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $420.8M $262.6M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $297.7M $312.9M
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$123.1M (net cash) $50.3M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.47 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. –
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. 13.3 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. 1.5 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 1.4 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 2.4 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
ANI PharmaceuticalsANIP (this company) $1.6B13.31.5+26%11.2%
PrecigenPGEN $1.5B61.99.6–15.6%
Zenas BioPharmaZBIO $1.6Bloss–––
Agios PharmaceuticalsAGIO $1.7Bloss11.7+214%-265%
Pacira BioSciencesPCRX $1.5B38.82.0+3.7%5.1%
Ultragenyx PharmaceuticalRARE $1.7Bloss2.3+16%-71.7%

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+28%

$290.8M vs $227.8M (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

+121%

$13.5M vs $6.1M (quarter ended 30 Sep 2026)

Insider buy/sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$2.4M

bought $0, sold $2.4M

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

-5.3%

288 13F filers vs 304

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

–

No 13F holdings or share count.

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

–

3.6M shares sold short (30 Oct 2026); no share count in the company's filings in our data

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

11.9

3.6M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+3.2%

3.5M shares sold short in the report before, 3.6M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

65%

65% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 61%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

32

Tracked since 21 Nov 2026

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

Tracking started 21 Nov 2026; the change shows after 30 days.

News Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

15

15 articles in the last 7 days; its usual week has 4 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

3.8×

15 articles in the last 7 days; its usual week has 4.

Unusual now sharp changes in the last 90 days, compared with its own past

  • Capital spending $13.5M, 2.2× a year earlier

Price $68.55 on 20 Nov 2026, -13% over 12 months (12-month range $67.41 to $86.03)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $14.0M in the last 12 months (the 12 months before: -$40.2M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 25 published in the last 12 months, +1150% on the 12 months before.
Revenue per quarter. Revenue $290.8M in the latest quarter, +28% on a year earlier.
Capital spending per quarter. Capital spending $13.5M in the latest quarter, +121% on a year earlier.
Institutional holders (13F filers). 288 13F filers reported holding it in the latest 13F quarter, +12% on a year earlier.
Lobbying spend. Lobbying spend: $0 published in the last 12 months.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
10 Nov 2026Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 13.5M vs usual 3.5M (2026-09-30); 2.2x the same period a year earlier
24 Aug 20268-K and other filingsDirector or officer change
24 Aug 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
21 May 20268-K and other filingsDirector or officer change
21 May 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
7 Apr 20268-K and other filingsChanged its auditor
1 Dec 20258-K and other filingsDirector or officer change
1 Dec 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
18 Nov 2025Sharp changeMany funds opening a new position: many funds opening a new position, 58 vs usual 25 (2025-09-30); 1.8x the same period a year earlier
11 Nov 2025Sharp changeQuarterly revenue change: quarterly revenue change, 227.8M vs usual 143.2M (2025-09-30); 1.5x the same period a year earlier
12 Aug 2025Sharp changeQuarterly revenue change: quarterly revenue change, 211.4M vs usual 137.7M (2025-06-30); 1.5x the same period a year earlier
23 May 20258-K and other filingsDirector or officer change
23 May 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
15 May 2025Sharp changeMany funds opening a new position: many funds opening a new position, 43 vs usual 24 (2025-03-31); 1.1x the same period a year earlier
13 May 2025Sharp changeQuarterly revenue change: quarterly revenue change, 197.1M vs usual 134.6M (2025-03-31); 1.4x the same period a year earlier
4 Mar 2025Sharp changeQuarterly revenue change: quarterly revenue change, 190.6M vs usual 131.7M (2024-12-31); 1.4x the same period a year earlier
18 Feb 2025Sharp changeShort interest spike: short interest spike, 2.3M vs usual 383K (2025-01-31); 9.3x the same period a year earlier
28 Jan 2025Sharp changeShort interest spike: short interest spike, 2.3M vs usual 373K (2025-01-15); 10.2x the same period a year earlier
14 Jan 2025Sharp changeShort interest spike: short interest spike, 2.1M vs usual 354K (2024-12-31); 8.1x the same period a year earlier
31 Dec 2024Sharp changeShort interest spike: short interest spike, 2.4M vs usual 354K (2024-12-13); 5.9x the same period a year earlier
17 Dec 2024Sharp changeShort interest spike: short interest spike, 1.8M vs usual 354K (2024-11-29); 4.6x the same period a year earlier
3 Dec 2024Sharp changeShort interest spike: short interest spike, 2.1M vs usual 354K (2024-11-15); 5.6x the same period a year earlier
19 Nov 2024Sharp changeShort interest spike: short interest spike, 2.2M vs usual 354K (2024-10-31); 5.1x the same period a year earlier
29 Oct 2024Sharp changeShort interest spike: short interest spike, 2.0M vs usual 354K (2024-10-15); 4.9x the same period a year earlier
15 Oct 2024Sharp changeShort interest spike: short interest spike, 2.3M vs usual 354K (2024-09-30); 5.1x the same period a year earlier
1 Oct 2024Sharp changeShort interest spike: short interest spike, 2.2M vs usual 324K (2024-09-13); 7.3x the same period a year earlier
20 Sep 20248-K and other filingsCompleted an acquisition or asset sale
17 Sep 2024Sharp changeShort interest spike: short interest spike, 2.4M vs usual 308K (2024-08-30); 9.1x the same period a year earlier
27 Aug 2024Sharp changeShort interest spike: short interest spike, 1.7M vs usual 296K (2024-08-15); 5.8x the same period a year earlier
13 Aug 20248-K and other filingsA major agreement ended
23 May 20248-K and other filingsDirector or officer change
23 May 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
23 Aug 20238-K and other filingsDirector or officer change
15 Aug 2023Sharp changeMany funds opening a new position: many funds opening a new position, 39 vs usual 16 (2023-06-30); 3.2x the same period a year earlier
25 May 20238-K and other filingsDirector or officer change
8 May 20238-K and other filingsDirector or officer change
8 May 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
14 Mar 2023Sharp changeQuarterly revenue change: quarterly revenue change, 94.2M vs usual 59.1M (2022-12-31); 1.5x the same period a year earlier
15 Nov 2022Sharp changeQuarterly revenue change: quarterly revenue change, 83.8M vs usual 55.9M (2022-09-30); 1.6x the same period a year earlier
19 Oct 2022Lobbying filinglobbying engagement terminated (THE CONAFAY GROUP, LLC)
9 Aug 2022Sharp changeQuarterly revenue change: quarterly revenue change, 73.9M vs usual 53.8M (2022-06-30); 1.5x the same period a year earlier
14 Jun 2022Sharp changeShort interest spike: short interest spike, 679K vs usual 471K (2022-05-31); 1.3x the same period a year earlier
2 Jun 20228-K and other filingsRestructuring costs announced
29 Apr 20228-K and other filingsDirector or officer change
11 Apr 2022Lobbying filingnew lobbying registration (THE CONAFAY GROUP, LLC)
23 Mar 20228-K and other filingsDirector or officer change
28 Feb 20228-K and other filingsDirector or officer change
28 Feb 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
15 Feb 2022Sharp changeMany funds opening a new position: many funds opening a new position, 28 vs usual 13.50 (2021-12-31); 2.2x the same period a year earlier
23 Dec 2021Sharp changeClustered insider buying: clustered insider buying (3 independent filers, 3 filing(s) in 30 days, value_usd total 275K)
25 Nov 20218-K and other filingsDirector or officer change
25 Nov 20218-K and other filingsA major agreement ended
25 Nov 20218-K and other filingsCompleted an acquisition or asset sale
25 Nov 2021Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Dec 2021: $275K published
Month from 1 Mar 2022: $890K published
Month from 1 Aug 2022: -$673K published
Month from 1 Dec 2022: -$7.7M published
Month from 1 Jun 2023: -$3.1M published
Month from 1 Jul 2023: -$3.6M published
Month from 1 Aug 2023: -$25.4M published
Month from 1 Sep 2023: -$4.4M published
Month from 1 Oct 2023: -$4.0M published
Month from 1 Nov 2023: -$2.9M published
Month from 1 Dec 2023: -$2.6M published
Month from 1 Jan 2024: -$2.8M published
Month from 1 Feb 2024: -$14K published
Month from 1 Mar 2024: -$10.5M published
Month from 1 Apr 2024: -$4.6M published
Month from 1 May 2024: -$5.9M published
Month from 1 Jun 2024: -$4.8M published
Month from 1 Jul 2024: -$4.5M published
Month from 1 Aug 2024: -$15K published
Month from 1 Sep 2024: -$14K published
Month from 1 Oct 2024: -$14K published
Month from 1 Nov 2024: -$2.3M published
Month from 1 Dec 2024: -$492K published
Month from 1 Jan 2025: -$22K published
Month from 1 Feb 2025: -$84K published
Month from 1 Mar 2025: -$531K published
Month from 1 Apr 2025: -$28K published
Month from 1 May 2025: -$373K published
Month from 1 Jun 2025: -$25K published
Month from 1 Jul 2025: -$26K published
Month from 1 Aug 2025: -$35.6M published
Month from 1 Sep 2025: -$830K published
Month from 1 Oct 2025: -$36K published
Month from 1 Nov 2025: -$2.1M published
Month from 1 Dec 2025: -$313K published
Month from 1 Jan 2026: -$42K published
Month from 1 Feb 2026: -$1.3M published
Month from 1 Mar 2026: -$2.7M published
Month from 1 Apr 2026: -$39K published
Month from 1 May 2026: -$5.7M published
Month from 1 Jun 2026: -$468K published
Month from 1 Jul 2026: -$797K published
Month from 1 Aug 2026: -$682K published
Month from 1 Sep 2026: -$698K published
Month from 1 Oct 2026: -$841K published
Month from 1 Nov 2026: -$420K published
H-1B/E-3 applications certified
Quarter from 1 Jan 2025: 1 published
Quarter from 1 Jul 2025: 1 published
Quarter from 1 Apr 2026: 1 published
Quarter from 1 Jul 2026: 1 published
Quarter from 1 Oct 2026: 23 published
Revenue per quarter
Quarter ended 31 Dec 2021: $60.9M, +6.4% on a year earlier; public on 16 Mar 2022
Quarter ended 31 Mar 2022: $64.5M, +18% on a year earlier; public on 11 May 2022
Quarter ended 30 Jun 2022: $73.9M, +52% on a year earlier; public on 9 Aug 2022
Quarter ended 30 Sep 2022: $83.8M, +61% on a year earlier; public on 10 Nov 2022
Quarter ended 31 Dec 2022: $94.2M, +55% on a year earlier; public on 10 Mar 2023
Quarter ended 31 Mar 2023: $106.8M, +66% on a year earlier; public on 9 May 2023
Quarter ended 30 Jun 2023: $116.5M, +58% on a year earlier; public on 10 Aug 2023
Quarter ended 30 Sep 2023: $131.8M, +57% on a year earlier; public on 9 Nov 2023
Quarter ended 31 Dec 2023: $131.7M, +40% on a year earlier; public on 1 Mar 2024
Quarter ended 31 Mar 2024: $137.4M, +29% on a year earlier; public on 11 May 2024
Quarter ended 30 Jun 2024: $138.0M, +18% on a year earlier; public on 7 Aug 2024
Quarter ended 30 Sep 2024: $148.3M, +13% on a year earlier; public on 9 Nov 2024
Quarter ended 31 Dec 2024: $190.6M, +45% on a year earlier; public on 1 Mar 2025
Quarter ended 31 Mar 2025: $197.1M, +43% on a year earlier; public on 10 May 2025
Quarter ended 30 Jun 2025: $211.4M, +53% on a year earlier; public on 9 Aug 2025
Quarter ended 30 Sep 2025: $227.8M, +54% on a year earlier; public on 8 Nov 2025
Quarter ended 31 Dec 2025: $247.1M, +30% on a year earlier; public on 28 Feb 2026
Quarter ended 31 Mar 2026: $237.5M, +20% on a year earlier; public on 9 May 2026
Quarter ended 30 Jun 2026: $266.0M, +26% on a year earlier; public on 8 Aug 2026
Quarter ended 30 Sep 2026: $290.8M, +28% on a year earlier; public on 6 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $356K, -83% on a year earlier; public on 16 Mar 2022
Quarter ended 31 Mar 2022: $1.9M, +179% on a year earlier; public on 11 May 2022
Quarter ended 30 Jun 2022: $1.3M, +42% on a year earlier; public on 9 Aug 2022
Quarter ended 30 Sep 2022: $2.5M, +332% on a year earlier; public on 10 Nov 2022
Quarter ended 31 Dec 2022: $3.1M, +781% on a year earlier; public on 10 Mar 2023
Quarter ended 31 Mar 2023: $2.3M, +21% on a year earlier; public on 9 May 2023
Quarter ended 30 Jun 2023: $2.5M, +89% on a year earlier; public on 10 Aug 2023
Quarter ended 30 Sep 2023: $1.7M, -30% on a year earlier; public on 9 Nov 2023
Quarter ended 31 Dec 2023: $2.3M, -27% on a year earlier; public on 1 Mar 2024
Quarter ended 31 Mar 2024: $4.6M, +95% on a year earlier; public on 11 May 2024
Quarter ended 30 Jun 2024: $4.4M, +78% on a year earlier; public on 7 Aug 2024
Quarter ended 30 Sep 2024: $4.8M, +177% on a year earlier; public on 9 Nov 2024
Quarter ended 31 Dec 2024: $2.4M, +5.0% on a year earlier; public on 1 Mar 2025
Quarter ended 31 Mar 2025: $2.5M, -46% on a year earlier; public on 10 May 2025
Quarter ended 30 Jun 2025: $4.0M, -9.8% on a year earlier; public on 9 Aug 2025
Quarter ended 30 Sep 2025: $6.1M, +27% on a year earlier; public on 8 Nov 2025
Quarter ended 31 Dec 2025: $1.2M, -48% on a year earlier; public on 28 Feb 2026
Quarter ended 31 Mar 2026: $6.1M, +146% on a year earlier; public on 9 May 2026
Quarter ended 30 Jun 2026: $3.1M, -24% on a year earlier; public on 8 Aug 2026
Quarter ended 30 Sep 2026: $13.5M, +121% on a year earlier; public on 6 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 118; public on 14 Feb 2022
31 Mar 2022 report: 118; public on 16 May 2022
30 Jun 2022 report: 114; public on 15 Aug 2022
30 Sep 2022 report: 112; public on 14 Nov 2022
31 Dec 2022 report: 113; public on 14 Feb 2023
31 Mar 2023 report: 134; public on 15 May 2023
30 Jun 2023 report: 156; public on 14 Aug 2023
30 Sep 2023 report: 170; public on 14 Nov 2023
31 Dec 2023 report: 170; public on 14 Feb 2024
31 Mar 2024 report: 193; public on 15 May 2024
30 Jun 2024 report: 191; public on 14 Aug 2024
30 Sep 2024 report: 200; public on 14 Nov 2024
31 Dec 2024 report: 201; public on 14 Feb 2025
31 Mar 2025 report: 222; public on 15 May 2025
30 Jun 2025 report: 218; public on 14 Aug 2025
30 Sep 2025 report: 257; public on 14 Nov 2025
31 Dec 2025 report: 278; public on 17 Feb 2026
31 Mar 2026 report: 274; public on 15 May 2026
30 Jun 2026 report: 304; public on 14 Aug 2026
30 Sep 2026 report: 288; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Apr 2022: $10K published
Quarter from 1 Jul 2022: $10K published

What is unusual now

  • Made public in the last 90 days: it spent $13.5M on capital projects in the quarter ended 30 Sep 2026, 2.2× the same quarter last year.
  • Quarterly capital spending jump: spent $13.5M on capital projects in the quarter ended 30 Sep 2026, 2.2× the same quarter last year Public on 10 Nov 2026.
  • Insider net buying (open market): Insiders sold a net $14.0M in the last 12 months (the 12 months before: -$40.2M).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 25 published in the last 12 months, +1150% on the 12 months before.

Latest records

The names and amounts behind the totals, newest first

Last 90 days: 11 sales, $2.4M; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
18 Nov 2026Nikhil LalwaniPRESIDENT & CEOSellplanned in advance (10b5-1)5,400$71.22$385KForm 4
13 Nov 2026Meredith CookSR. VP, GENERAL COUNSEL & SEC.Sellplanned in advance (10b5-1)500$70.80$35KForm 4
30 Oct 2026Stephen P. CareySVP & CFOSellplanned in advance (10b5-1)2,850$72.87$208KForm 4
16 Oct 2026Nikhil LalwaniPRESIDENT & CEOSellplanned in advance (10b5-1)5,400$71.89$388KForm 4
13 Oct 2026Meredith CookSR. VP, GENERAL COUNSEL & SEC.Sellplanned in advance (10b5-1)500$73.59$37KForm 4
30 Sep 2026Stephen P. CareySVP & CFOSellplanned in advance (10b5-1)2,850$73.00$208KForm 4
16 Sep 2026Nikhil LalwaniPRESIDENT & CEOSellplanned in advance (10b5-1)5,400$71.00$383KForm 4
14 Sep 2026Meredith CookSR. VP, GENERAL COUNSEL & SEC.Sellplanned in advance (10b5-1)500$70.79$35KForm 4

288 institutions reported shares at the end of Q3 2026, 95% of the shares outstanding; 33 opened a position, 50 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Absolute Investment Advisers, LLC11.7M48.0%$13.7MNew+11.7M
BlackRock, Inc.3.2M12.9%$229.3M+197K+6.7%
Soleus Capital Management, L.P.976K3.99%$70.9M+108K+12%
State Street Corp951K3.89%$69.1M+119K+14%
American Century Companies Inc913K3.74%$66.3M+338K+59%
Vanguard Capital Management LLC905K3.70%$65.7M+66K+7.9%
Bank of New York Mellon Corp771K3.16%$9.5M+652K+550%
Dimensional Fund Advisors LP729K2.98%$52.9M+105K+17%
Tang Capital Management LLC708K2.90%$51.4MNo change
UBS Group AG621K2.54%$45.1M+324K+109%

Company events

All 47 company events

In 12 months: 3 director or officer changes, 1 auditor change, 1 major agreement. Results releases and routine reports are left out.

FiledWhat happenedSource
5 Nov 2026Signed a major agreementSame filing: took on new debt8-K
24 Aug 2026Director or officer change8-K
21 May 2026Director or officer changeSame filing: shareholder vote results8-K
7 Apr 2026Changed its auditor8-K
1 Dec 2025Director or officer change8-K
23 May 2025Director or officer changeSame filing: changed its bylaws or fiscal year, shareholder vote results8-K
20 Sep 2024Signed a major agreement; Completed an acquisition or asset sale8-K
13 Aug 2024Signed a major agreement; A major agreement endedSame filing: took on new debt, sold shares privately8-K

32 open postings; careers site tracked since 21 Nov 2026. Most in Finance & accounting 12%, Sales & business development 12%, Manufacturing & production 9%, People & recruiting 6%.

PostedJobLocation
20 Nov 2026Ophthalmology Account Executive - DenverSales & business developmentREMOTE, United States
19 Nov 2026Production Operator - Compression (1st Shift)Manufacturing & productionEast Windsor, NJ, United States
17 Nov 2026Ophthalmology Account Executive - WashingtonSales & business developmentREMOTE, United States
17 Nov 2026Ophthalmology Account Executive - BaltimoreSales & business developmentREMOTE, United States
16 Nov 2026Manufacturing Operator - New Starting Wage - $20/HRPeople & recruitingBaudette, MN, United States
16 Nov 2026Manufacturing Operator II/III – Train in Baudette, MN, Then Work in the Madison, WI AreaManufacturing & productionMiddleton, WI, United States
13 Nov 2026Packaging Team Lead - 2nd ShiftEast Windsor, NJ, United States
10 Nov 2026Ophthalmology Account Executive - Orlando/JacksonvilleSales & business developmentREMOTE, United States

Reported lobbying spend: $10K in Q2 2022, $10K in Q1 2022. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
31 Jul 2022EndedThe Conafay Group, LLCfor Ani PharmaceuticalsNot statedFiling
7 Feb 2022NewThe Conafay Group, LLCfor Ani PharmaceuticalsSupport for medical researchMEDFiling
30 Jun 2021EndedBuchanan Ingersoll & Rooney PCfor Ani Pharmaceuticals, Inc.Not statedFiling
12 Feb 2018NewBuchanan Ingersoll & Rooney PCfor Ani Pharmaceuticals, Inc.Federal government relations service, strategy development and implementation relating to status of FDAs action with regards to the companys NDA.Health issues, Pharmacy, MEDFiling

The 5 newest of 206 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

18 Nov 2025confirmed

Confirmed across sources Institutional holdings and Filings + Financials

ANI Pharmaceuticals (ANIP): reported revenue of $227.8M for the quarter ended 30 Sep 2025, 1.5× the same quarter last year, while it saw 58 13F filers open a new position in the quarter ended 30 Sep 2025, 1.8× the same quarter last year. Two unrelated kinds of activity within 7 days.

  • Financials: Quarterly revenue change, became public on 11 Nov 2025
  • Institutional holdings: Many funds opening a new position, became public on 14 Nov 2025
2023-09-30: $131.8M2023-12-31: $131.7M2024-03-31: $137.4M2024-06-30: $138.0M2024-09-30: $148.3M2024-12-31: $190.6M2025-03-31: $197.1M2025-06-30: $211.4M2025-09-30: $227.8M
The quarter ended 30 Sep 2025 against the 8 quarters before it. this quarterearliernormal: $143.2M
See the evidence (2 changes)

Financials: Quarterly revenue change became public on 11 Nov 2025

ANI Pharmaceuticals reported revenue of $227.8M for the quarter ended 30 Sep 2025, 1.5× the same quarter last year.

This period
$227.8M (the quarter ended 30 Sep 2025)
Normal quarter (median of 8 earlier)
$143.2M
Typical spread (median absolute deviation)
$11.4M
How far from its usual level
+5.0
Same quarter last year
$148.3M
History used
5,479 days
2023-09-30: $131.8M2023-12-31: $131.7M2024-03-31: $137.4M2024-06-30: $138.0M2024-09-30: $148.3M2024-12-31: $190.6M2025-03-31: $197.1M2025-06-30: $211.4M2025-09-30: $227.8M
the quarter ended 30 Sep 20258 earlier quartersnormal: $143.2M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Institutional holdings: Many funds opening a new position became public on 14 Nov 2025

ANI Pharmaceuticals saw 58 13F filers open a new position in the quarter ended 30 Sep 2025, 1.8× the same quarter last year.

This period
58 (the quarter ended 30 Sep 2025)
Normal quarter (median of 8 earlier)
25
Typical spread (median absolute deviation)
3
How far from its usual level
+7.4
Same quarter last year
32
History used
4,383 days
2023-09-30: 242023-12-31: 212024-03-31: 382024-06-30: 232024-09-30: 322024-12-31: 242025-03-31: 432025-06-30: 262025-09-30: 58
the quarter ended 30 Sep 20258 earlier quartersnormal: 25

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

15 May 2025confirmed

Confirmed across sources Institutional holdings and Filings + Financials

ANI Pharmaceuticals (ANIP): reported revenue of $197.1M for the quarter ended 31 Mar 2025, 1.4× the same quarter last year, while it saw 43 13F filers open a new position in the quarter ended 31 Mar 2025, 1.1× the same quarter last year. Two unrelated kinds of activity within 2 days.

  • Financials: Quarterly revenue change, became public on 13 May 2025
  • Institutional holdings: Many funds opening a new position, became public on 15 May 2025
2023-03-31: $106.8M2023-06-30: $116.5M2023-09-30: $131.8M2023-12-31: $131.7M2024-03-31: $137.4M2024-06-30: $138.0M2024-09-30: $148.3M2024-12-31: $190.6M2025-03-31: $197.1M
The quarter ended 31 Mar 2025 against the 8 quarters before it. this quarterearliernormal: $134.6M
See the evidence (2 changes)

Financials: Quarterly revenue change became public on 13 May 2025

ANI Pharmaceuticals reported revenue of $197.1M for the quarter ended 31 Mar 2025, 1.4× the same quarter last year.

This period
$197.1M (the quarter ended 31 Mar 2025)
Normal quarter (median of 8 earlier)
$134.6M
Typical spread (median absolute deviation)
$8.6M
How far from its usual level
+4.6
Same quarter last year
$137.4M
History used
5,296 days
2023-03-31: $106.8M2023-06-30: $116.5M2023-09-30: $131.8M2023-12-31: $131.7M2024-03-31: $137.4M2024-06-30: $138.0M2024-09-30: $148.3M2024-12-31: $190.6M2025-03-31: $197.1M
the quarter ended 31 Mar 20258 earlier quartersnormal: $134.6M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Institutional holdings: Many funds opening a new position became public on 15 May 2025

ANI Pharmaceuticals saw 43 13F filers open a new position in the quarter ended 31 Mar 2025, 1.1× the same quarter last year.

This period
43 (the quarter ended 31 Mar 2025)
Normal quarter (median of 8 earlier)
24
Typical spread (median absolute deviation)
3.5
How far from its usual level
+3.7
Same quarter last year
38
History used
4,200 days
2023-03-31: 202023-06-30: 392023-09-30: 242023-12-31: 212024-03-31: 382024-06-30: 232024-09-30: 322024-12-31: 242025-03-31: 43
the quarter ended 31 Mar 20258 earlier quartersnormal: 24

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

4 Mar 2025confirmed

Confirmed across sources Filings + Financials and Short interest and volume

ANI Pharmaceuticals (ANIP): had 2.3M shares sold short in the 31 Jan 2025 report, 9.3× the same report last year, while it reported revenue of $190.6M for the quarter ended 31 Dec 2024, 1.4× the same quarter last year. Two unrelated kinds of activity within 14 days.

  • Short interest and volume: Short interest spike, became public on 12 Feb 2025
  • Financials: Quarterly revenue change, became public on 4 Mar 2025
2024-01-31: 242K2024-02-15: 213K2024-02-29: 249K2024-03-15: 262K2024-03-28: 197K2024-04-15: 214K2024-04-30: 230K2024-05-15: 204K2024-05-31: 339K2024-06-14: 376K2024-06-28: 369K2024-07-15: 390K2024-07-31: 309K2024-08-15: 1.7M2024-08-30: 2.4M2024-09-13: 2.2M2024-09-30: 2.3M2024-10-15: 2.0M2024-10-31: 2.2M2024-11-15: 2.1M2024-11-29: 1.8M2024-12-13: 2.4M2024-12-31: 2.1M2025-01-15: 2.3M2025-01-31: 2.3M
The 31 Jan 2025 report against the 24 reports before it. this reportearliernormal: 383K
See the evidence (2 changes)

Short interest and volume: Short interest spike became public on 12 Feb 2025

ANI Pharmaceuticals had 2.3M shares sold short in the 31 Jan 2025 report, 9.3× the same report last year.

This period
2.3M (the 31 Jan 2025 report)
Normal report (median of 24 earlier)
383K
Typical spread (median absolute deviation)
183K
How far from its usual level
+6.9
Same report last year
242K
History used
2,590 days
2024-01-31: 242K2024-02-15: 213K2024-02-29: 249K2024-03-15: 262K2024-03-28: 197K2024-04-15: 214K2024-04-30: 230K2024-05-15: 204K2024-05-31: 339K2024-06-14: 376K2024-06-28: 369K2024-07-15: 390K2024-07-31: 309K2024-08-15: 1.7M2024-08-30: 2.4M2024-09-13: 2.2M2024-09-30: 2.3M2024-10-15: 2.0M2024-10-31: 2.2M2024-11-15: 2.1M2024-11-29: 1.8M2024-12-13: 2.4M2024-12-31: 2.1M2025-01-15: 2.3M2025-01-31: 2.3M
the 31 Jan 2025 report24 earlier reportsnormal: 383K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Financials: Quarterly revenue change became public on 4 Mar 2025

ANI Pharmaceuticals reported revenue of $190.6M for the quarter ended 31 Dec 2024, 1.4× the same quarter last year.

This period
$190.6M (the quarter ended 31 Dec 2024)
Normal quarter (median of 8 earlier)
$131.7M
Typical spread (median absolute deviation)
$10.7M
How far from its usual level
+3.7
Same quarter last year
$131.7M
History used
5,206 days
2022-12-31: $94.2M2023-03-31: $106.8M2023-06-30: $116.5M2023-09-30: $131.8M2023-12-31: $131.7M2024-03-31: $137.4M2024-06-30: $138.0M2024-09-30: $148.3M2024-12-31: $190.6M
the quarter ended 31 Dec 20248 earlier quartersnormal: $131.7M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 10 Nov 2026Financials change

    spent $13.5M on capital projects in the quarter ended 30 Sep 2026, 2.2× the same quarter last year.

    Same quarter last year: $6.1M; its normal quarter is $3.5M.

    See the evidence
    This period
    $13.5M (the quarter ended 30 Sep 2026)
    Normal quarter (median of 8 earlier)
    $3.5M
    Typical spread (median absolute deviation)
    $1.2M
    How far from its usual level
    +5.6
    Same quarter last year
    $6.1M
    History used
    5,844 days
    2024-09-30: $4.8M2024-12-31: $2.4M2025-03-31: $2.5M2025-06-30: $4.0M2025-09-30: $6.1M2025-12-31: $1.2M2026-03-31: $6.1M2026-06-30: $3.1M2026-09-30: $13.5M
    the quarter ended 30 Sep 20268 earlier quartersnormal: $3.5M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  2. 24 Aug 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  3. 24 Aug 2026Filings record

    Director or officer change

  4. 21 May 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  5. 21 May 2026Filings record

    Director or officer change

  6. 7 Apr 2026Filings record

    Changed its auditor

  7. 1 Dec 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  8. 1 Dec 2025Filings record

    Director or officer change

  9. 18 Nov 2025several at once

    reported revenue of $227.8M for the quarter ended 30 Sep 2025, 1.5× the same quarter last year, while it saw 58 13F filers open a new position in the quarter ended 30 Sep 2025, 1.8× the same quarter last year. Two unrelated kinds of activity within 7 days.

    See the evidence (2 changes)

    Financials: Quarterly revenue change became public on 11 Nov 2025

    ANI Pharmaceuticals reported revenue of $227.8M for the quarter ended 30 Sep 2025, 1.5× the same quarter last year.

    This period
    $227.8M (the quarter ended 30 Sep 2025)
    Normal quarter (median of 8 earlier)
    $143.2M
    Typical spread (median absolute deviation)
    $11.4M
    How far from its usual level
    +5.0
    Same quarter last year
    $148.3M
    History used
    5,479 days
    2023-09-30: $131.8M2023-12-31: $131.7M2024-03-31: $137.4M2024-06-30: $138.0M2024-09-30: $148.3M2024-12-31: $190.6M2025-03-31: $197.1M2025-06-30: $211.4M2025-09-30: $227.8M
    the quarter ended 30 Sep 20258 earlier quartersnormal: $143.2M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Institutional holdings: Many funds opening a new position became public on 14 Nov 2025

    ANI Pharmaceuticals saw 58 13F filers open a new position in the quarter ended 30 Sep 2025, 1.8× the same quarter last year.

    This period
    58 (the quarter ended 30 Sep 2025)
    Normal quarter (median of 8 earlier)
    25
    Typical spread (median absolute deviation)
    3
    How far from its usual level
    +7.4
    Same quarter last year
    32
    History used
    4,383 days
    2023-09-30: 242023-12-31: 212024-03-31: 382024-06-30: 232024-09-30: 322024-12-31: 242025-03-31: 432025-06-30: 262025-09-30: 58
    the quarter ended 30 Sep 20258 earlier quartersnormal: 25

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  10. 14 Nov 2025Institutional holdings change

    saw 58 13F filers open a new position in the quarter ended 30 Sep 2025, 1.8× the same quarter last year.

    Same quarter last year: 32; its normal quarter is 25.

    See the evidence
    This period
    58 (the quarter ended 30 Sep 2025)
    Normal quarter (median of 8 earlier)
    25
    Typical spread (median absolute deviation)
    3
    How far from its usual level
    +7.4
    Same quarter last year
    32
    History used
    4,383 days
    2023-09-30: 242023-12-31: 212024-03-31: 382024-06-30: 232024-09-30: 322024-12-31: 242025-03-31: 432025-06-30: 262025-09-30: 58
    the quarter ended 30 Sep 20258 earlier quartersnormal: 25

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  11. 11 Nov 2025Financials change

    reported revenue of $227.8M for the quarter ended 30 Sep 2025, 1.5× the same quarter last year.

    Same quarter last year: $148.3M; its normal quarter is $143.2M.

    See the evidence
    This period
    $227.8M (the quarter ended 30 Sep 2025)
    Normal quarter (median of 8 earlier)
    $143.2M
    Typical spread (median absolute deviation)
    $11.4M
    How far from its usual level
    +5.0
    Same quarter last year
    $148.3M
    History used
    5,479 days
    2023-09-30: $131.8M2023-12-31: $131.7M2024-03-31: $137.4M2024-06-30: $138.0M2024-09-30: $148.3M2024-12-31: $190.6M2025-03-31: $197.1M2025-06-30: $211.4M2025-09-30: $227.8M
    the quarter ended 30 Sep 20258 earlier quartersnormal: $143.2M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  12. 12 Aug 2025Financials change

    reported revenue of $211.4M for the quarter ended 30 Jun 2025, 1.5× the same quarter last year.

    Same quarter last year: $138.0M; its normal quarter is $137.7M.

    See the evidence
    This period
    $211.4M (the quarter ended 30 Jun 2025)
    Normal quarter (median of 8 earlier)
    $137.7M
    Typical spread (median absolute deviation)
    $8.3M
    How far from its usual level
    +5.3
    Same quarter last year
    $138.0M
    History used
    5,387 days
    2023-06-30: $116.5M2023-09-30: $131.8M2023-12-31: $131.7M2024-03-31: $137.4M2024-06-30: $138.0M2024-09-30: $148.3M2024-12-31: $190.6M2025-03-31: $197.1M2025-06-30: $211.4M
    the quarter ended 30 Jun 20258 earlier quartersnormal: $137.7M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  13. 23 May 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  14. 23 May 2025Filings record

    Director or officer change

  15. 15 May 2025several at once

    reported revenue of $197.1M for the quarter ended 31 Mar 2025, 1.4× the same quarter last year, while it saw 43 13F filers open a new position in the quarter ended 31 Mar 2025, 1.1× the same quarter last year. Two unrelated kinds of activity within 2 days.

    See the evidence (2 changes)

    Financials: Quarterly revenue change became public on 13 May 2025

    ANI Pharmaceuticals reported revenue of $197.1M for the quarter ended 31 Mar 2025, 1.4× the same quarter last year.

    This period
    $197.1M (the quarter ended 31 Mar 2025)
    Normal quarter (median of 8 earlier)
    $134.6M
    Typical spread (median absolute deviation)
    $8.6M
    How far from its usual level
    +4.6
    Same quarter last year
    $137.4M
    History used
    5,296 days
    2023-03-31: $106.8M2023-06-30: $116.5M2023-09-30: $131.8M2023-12-31: $131.7M2024-03-31: $137.4M2024-06-30: $138.0M2024-09-30: $148.3M2024-12-31: $190.6M2025-03-31: $197.1M
    the quarter ended 31 Mar 20258 earlier quartersnormal: $134.6M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Institutional holdings: Many funds opening a new position became public on 15 May 2025

    ANI Pharmaceuticals saw 43 13F filers open a new position in the quarter ended 31 Mar 2025, 1.1× the same quarter last year.

    This period
    43 (the quarter ended 31 Mar 2025)
    Normal quarter (median of 8 earlier)
    24
    Typical spread (median absolute deviation)
    3.5
    How far from its usual level
    +3.7
    Same quarter last year
    38
    History used
    4,200 days
    2023-03-31: 202023-06-30: 392023-09-30: 242023-12-31: 212024-03-31: 382024-06-30: 232024-09-30: 322024-12-31: 242025-03-31: 43
    the quarter ended 31 Mar 20258 earlier quartersnormal: 24

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  16. 15 May 2025Institutional holdings change

    saw 43 13F filers open a new position in the quarter ended 31 Mar 2025, 1.1× the same quarter last year.

    Same quarter last year: 38; its normal quarter is 24.

    See the evidence
    This period
    43 (the quarter ended 31 Mar 2025)
    Normal quarter (median of 8 earlier)
    24
    Typical spread (median absolute deviation)
    3.5
    How far from its usual level
    +3.7
    Same quarter last year
    38
    History used
    4,200 days
    2023-03-31: 202023-06-30: 392023-09-30: 242023-12-31: 212024-03-31: 382024-06-30: 232024-09-30: 322024-12-31: 242025-03-31: 43
    the quarter ended 31 Mar 20258 earlier quartersnormal: 24

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  17. 13 May 2025Financials change

    reported revenue of $197.1M for the quarter ended 31 Mar 2025, 1.4× the same quarter last year.

    Same quarter last year: $137.4M; its normal quarter is $134.6M.

    See the evidence
    This period
    $197.1M (the quarter ended 31 Mar 2025)
    Normal quarter (median of 8 earlier)
    $134.6M
    Typical spread (median absolute deviation)
    $8.6M
    How far from its usual level
    +4.6
    Same quarter last year
    $137.4M
    History used
    5,296 days
    2023-03-31: $106.8M2023-06-30: $116.5M2023-09-30: $131.8M2023-12-31: $131.7M2024-03-31: $137.4M2024-06-30: $138.0M2024-09-30: $148.3M2024-12-31: $190.6M2025-03-31: $197.1M
    the quarter ended 31 Mar 20258 earlier quartersnormal: $134.6M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  18. 4 Mar 2025several at once

    had 2.3M shares sold short in the 31 Jan 2025 report, 9.3× the same report last year, while it reported revenue of $190.6M for the quarter ended 31 Dec 2024, 1.4× the same quarter last year. Two unrelated kinds of activity within 14 days.

    See the evidence (2 changes)

    Short interest and volume: Short interest spike became public on 12 Feb 2025

    ANI Pharmaceuticals had 2.3M shares sold short in the 31 Jan 2025 report, 9.3× the same report last year.

    This period
    2.3M (the 31 Jan 2025 report)
    Normal report (median of 24 earlier)
    383K
    Typical spread (median absolute deviation)
    183K
    How far from its usual level
    +6.9
    Same report last year
    242K
    History used
    2,590 days
    2024-01-31: 242K2024-02-15: 213K2024-02-29: 249K2024-03-15: 262K2024-03-28: 197K2024-04-15: 214K2024-04-30: 230K2024-05-15: 204K2024-05-31: 339K2024-06-14: 376K2024-06-28: 369K2024-07-15: 390K2024-07-31: 309K2024-08-15: 1.7M2024-08-30: 2.4M2024-09-13: 2.2M2024-09-30: 2.3M2024-10-15: 2.0M2024-10-31: 2.2M2024-11-15: 2.1M2024-11-29: 1.8M2024-12-13: 2.4M2024-12-31: 2.1M2025-01-15: 2.3M2025-01-31: 2.3M
    the 31 Jan 2025 report24 earlier reportsnormal: 383K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Financials: Quarterly revenue change became public on 4 Mar 2025

    ANI Pharmaceuticals reported revenue of $190.6M for the quarter ended 31 Dec 2024, 1.4× the same quarter last year.

    This period
    $190.6M (the quarter ended 31 Dec 2024)
    Normal quarter (median of 8 earlier)
    $131.7M
    Typical spread (median absolute deviation)
    $10.7M
    How far from its usual level
    +3.7
    Same quarter last year
    $131.7M
    History used
    5,206 days
    2022-12-31: $94.2M2023-03-31: $106.8M2023-06-30: $116.5M2023-09-30: $131.8M2023-12-31: $131.7M2024-03-31: $137.4M2024-06-30: $138.0M2024-09-30: $148.3M2024-12-31: $190.6M
    the quarter ended 31 Dec 20248 earlier quartersnormal: $131.7M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  19. 4 Mar 2025Financials change

    reported revenue of $190.6M for the quarter ended 31 Dec 2024, 1.4× the same quarter last year.

    Same quarter last year: $131.7M; its normal quarter is $131.7M.

    See the evidence
    This period
    $190.6M (the quarter ended 31 Dec 2024)
    Normal quarter (median of 8 earlier)
    $131.7M
    Typical spread (median absolute deviation)
    $10.7M
    How far from its usual level
    +3.7
    Same quarter last year
    $131.7M
    History used
    5,206 days
    2022-12-31: $94.2M2023-03-31: $106.8M2023-06-30: $116.5M2023-09-30: $131.8M2023-12-31: $131.7M2024-03-31: $137.4M2024-06-30: $138.0M2024-09-30: $148.3M2024-12-31: $190.6M
    the quarter ended 31 Dec 20248 earlier quartersnormal: $131.7M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  20. 12 Feb 2025Short interest and volume change

    had 2.3M shares sold short in the 31 Jan 2025 report, 9.3× the same report last year.

    Same report last year: 242K; its normal report is 383K.

    See the evidence
    This period
    2.3M (the 31 Jan 2025 report)
    Normal report (median of 24 earlier)
    383K
    Typical spread (median absolute deviation)
    183K
    How far from its usual level
    +6.9
    Same report last year
    242K
    History used
    2,590 days
    2024-01-31: 242K2024-02-15: 213K2024-02-29: 249K2024-03-15: 262K2024-03-28: 197K2024-04-15: 214K2024-04-30: 230K2024-05-15: 204K2024-05-31: 339K2024-06-14: 376K2024-06-28: 369K2024-07-15: 390K2024-07-31: 309K2024-08-15: 1.7M2024-08-30: 2.4M2024-09-13: 2.2M2024-09-30: 2.3M2024-10-15: 2.0M2024-10-31: 2.2M2024-11-15: 2.1M2024-11-29: 1.8M2024-12-13: 2.4M2024-12-31: 2.1M2025-01-15: 2.3M2025-01-31: 2.3M
    the 31 Jan 2025 report24 earlier reportsnormal: 383K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  21. 28 Jan 2025Short interest and volume change

    had 2.3M shares sold short in the 15 Jan 2025 report, 10× the same report last year.

    Same report last year: 224K; its normal report is 373K.

    See the evidence
    This period
    2.3M (the 15 Jan 2025 report)
    Normal report (median of 24 earlier)
    373K
    Typical spread (median absolute deviation)
    164K
    How far from its usual level
    +7.9
    Same report last year
    224K
    History used
    2,574 days
    2024-01-12: 224K2024-01-31: 242K2024-02-15: 213K2024-02-29: 249K2024-03-15: 262K2024-03-28: 197K2024-04-15: 214K2024-04-30: 230K2024-05-15: 204K2024-05-31: 339K2024-06-14: 376K2024-06-28: 369K2024-07-15: 390K2024-07-31: 309K2024-08-15: 1.7M2024-08-30: 2.4M2024-09-13: 2.2M2024-09-30: 2.3M2024-10-15: 2.0M2024-10-31: 2.2M2024-11-15: 2.1M2024-11-29: 1.8M2024-12-13: 2.4M2024-12-31: 2.1M2025-01-15: 2.3M
    the 15 Jan 2025 report24 earlier reportsnormal: 373K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  22. 14 Jan 2025Short interest and volume change

    had 2.1M shares sold short in the 31 Dec 2024 report, 8.1× the same report last year.

    Same report last year: 264K; its normal report is 354K.

    See the evidence
    This period
    2.1M (the 31 Dec 2024 report)
    Normal report (median of 24 earlier)
    354K
    Typical spread (median absolute deviation)
    141K
    How far from its usual level
    +8.6
    Same report last year
    264K
    History used
    2,559 days
    2023-12-29: 264K2024-01-12: 224K2024-01-31: 242K2024-02-15: 213K2024-02-29: 249K2024-03-15: 262K2024-03-28: 197K2024-04-15: 214K2024-04-30: 230K2024-05-15: 204K2024-05-31: 339K2024-06-14: 376K2024-06-28: 369K2024-07-15: 390K2024-07-31: 309K2024-08-15: 1.7M2024-08-30: 2.4M2024-09-13: 2.2M2024-09-30: 2.3M2024-10-15: 2.0M2024-10-31: 2.2M2024-11-15: 2.1M2024-11-29: 1.8M2024-12-13: 2.4M2024-12-31: 2.1M
    the 31 Dec 2024 report24 earlier reportsnormal: 354K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  23. 25 Dec 2024Short interest and volume change

    had 2.4M shares sold short in the 13 Dec 2024 report, 5.9× the same report last year.

    Same report last year: 400K; its normal report is 354K.

    See the evidence
    This period
    2.4M (the 13 Dec 2024 report)
    Normal report (median of 24 earlier)
    354K
    Typical spread (median absolute deviation)
    135K
    How far from its usual level
    +9.9
    Same report last year
    400K
    History used
    2,541 days
    2023-12-15: 400K2023-12-29: 264K2024-01-12: 224K2024-01-31: 242K2024-02-15: 213K2024-02-29: 249K2024-03-15: 262K2024-03-28: 197K2024-04-15: 214K2024-04-30: 230K2024-05-15: 204K2024-05-31: 339K2024-06-14: 376K2024-06-28: 369K2024-07-15: 390K2024-07-31: 309K2024-08-15: 1.7M2024-08-30: 2.4M2024-09-13: 2.2M2024-09-30: 2.3M2024-10-15: 2.0M2024-10-31: 2.2M2024-11-15: 2.1M2024-11-29: 1.8M2024-12-13: 2.4M
    the 13 Dec 2024 report24 earlier reportsnormal: 354K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  24. 11 Dec 2024Short interest and volume change

    had 1.8M shares sold short in the 29 Nov 2024 report, 4.6× the same report last year.

    Same report last year: 402K; its normal report is 354K.

    See the evidence
    This period
    1.8M (the 29 Nov 2024 report)
    Normal report (median of 24 earlier)
    354K
    Typical spread (median absolute deviation)
    127K
    How far from its usual level
    +7.9
    Same report last year
    402K
    History used
    2,527 days
    2023-11-30: 402K2023-12-15: 400K2023-12-29: 264K2024-01-12: 224K2024-01-31: 242K2024-02-15: 213K2024-02-29: 249K2024-03-15: 262K2024-03-28: 197K2024-04-15: 214K2024-04-30: 230K2024-05-15: 204K2024-05-31: 339K2024-06-14: 376K2024-06-28: 369K2024-07-15: 390K2024-07-31: 309K2024-08-15: 1.7M2024-08-30: 2.4M2024-09-13: 2.2M2024-09-30: 2.3M2024-10-15: 2.0M2024-10-31: 2.2M2024-11-15: 2.1M2024-11-29: 1.8M
    the 29 Nov 2024 report24 earlier reportsnormal: 354K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  25. 27 Nov 2024Short interest and volume change

    had 2.1M shares sold short in the 15 Nov 2024 report, 5.6× the same report last year.

    Same report last year: 377K; its normal report is 354K.

    See the evidence
    This period
    2.1M (the 15 Nov 2024 report)
    Normal report (median of 24 earlier)
    354K
    Typical spread (median absolute deviation)
    118K
    How far from its usual level
    +10.0
    Same report last year
    377K
    History used
    2,513 days
    2023-11-15: 377K2023-11-30: 402K2023-12-15: 400K2023-12-29: 264K2024-01-12: 224K2024-01-31: 242K2024-02-15: 213K2024-02-29: 249K2024-03-15: 262K2024-03-28: 197K2024-04-15: 214K2024-04-30: 230K2024-05-15: 204K2024-05-31: 339K2024-06-14: 376K2024-06-28: 369K2024-07-15: 390K2024-07-31: 309K2024-08-15: 1.7M2024-08-30: 2.4M2024-09-13: 2.2M2024-09-30: 2.3M2024-10-15: 2.0M2024-10-31: 2.2M2024-11-15: 2.1M
    the 15 Nov 2024 report24 earlier reportsnormal: 354K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  26. 13 Nov 2024Short interest and volume change

    had 2.2M shares sold short in the 31 Oct 2024 report, 5.1× the same report last year.

    Same report last year: 423K; its normal report is 354K.

    See the evidence
    This period
    2.2M (the 31 Oct 2024 report)
    Normal report (median of 24 earlier)
    354K
    Typical spread (median absolute deviation)
    108K
    How far from its usual level
    +11.2
    Same report last year
    423K
    History used
    2,498 days
    2023-10-31: 423K2023-11-15: 377K2023-11-30: 402K2023-12-15: 400K2023-12-29: 264K2024-01-12: 224K2024-01-31: 242K2024-02-15: 213K2024-02-29: 249K2024-03-15: 262K2024-03-28: 197K2024-04-15: 214K2024-04-30: 230K2024-05-15: 204K2024-05-31: 339K2024-06-14: 376K2024-06-28: 369K2024-07-15: 390K2024-07-31: 309K2024-08-15: 1.7M2024-08-30: 2.4M2024-09-13: 2.2M2024-09-30: 2.3M2024-10-15: 2.0M2024-10-31: 2.2M
    the 31 Oct 2024 report24 earlier reportsnormal: 354K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  27. 25 Oct 2024Short interest and volume change

    had 2.0M shares sold short in the 15 Oct 2024 report, 4.9× the same report last year.

    Same report last year: 415K; its normal report is 354K.

    See the evidence
    This period
    2.0M (the 15 Oct 2024 report)
    Normal report (median of 24 earlier)
    354K
    Typical spread (median absolute deviation)
    99K
    How far from its usual level
    +11.6
    Same report last year
    415K
    History used
    2,482 days
    2023-10-13: 415K2023-10-31: 423K2023-11-15: 377K2023-11-30: 402K2023-12-15: 400K2023-12-29: 264K2024-01-12: 224K2024-01-31: 242K2024-02-15: 213K2024-02-29: 249K2024-03-15: 262K2024-03-28: 197K2024-04-15: 214K2024-04-30: 230K2024-05-15: 204K2024-05-31: 339K2024-06-14: 376K2024-06-28: 369K2024-07-15: 390K2024-07-31: 309K2024-08-15: 1.7M2024-08-30: 2.4M2024-09-13: 2.2M2024-09-30: 2.3M2024-10-15: 2.0M
    the 15 Oct 2024 report24 earlier reportsnormal: 354K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  28. 10 Oct 2024Short interest and volume change

    had 2.3M shares sold short in the 30 Sep 2024 report, 5.1× the same report last year.

    Same report last year: 444K; its normal report is 354K.

    See the evidence
    This period
    2.3M (the 30 Sep 2024 report)
    Normal report (median of 24 earlier)
    354K
    Typical spread (median absolute deviation)
    91K
    How far from its usual level
    +14.2
    Same report last year
    444K
    History used
    2,467 days
    2023-09-29: 444K2023-10-13: 415K2023-10-31: 423K2023-11-15: 377K2023-11-30: 402K2023-12-15: 400K2023-12-29: 264K2024-01-12: 224K2024-01-31: 242K2024-02-15: 213K2024-02-29: 249K2024-03-15: 262K2024-03-28: 197K2024-04-15: 214K2024-04-30: 230K2024-05-15: 204K2024-05-31: 339K2024-06-14: 376K2024-06-28: 369K2024-07-15: 390K2024-07-31: 309K2024-08-15: 1.7M2024-08-30: 2.4M2024-09-13: 2.2M2024-09-30: 2.3M
    the 30 Sep 2024 report24 earlier reportsnormal: 354K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  29. 25 Sep 2024Short interest and volume change

    had 2.2M shares sold short in the 13 Sep 2024 report, 7.3× the same report last year.

    Same report last year: 306K; its normal report is 324K.

    See the evidence
    This period
    2.2M (the 13 Sep 2024 report)
    Normal report (median of 24 earlier)
    324K
    Typical spread (median absolute deviation)
    80K
    How far from its usual level
    +16.0
    Same report last year
    306K
    History used
    2,450 days
    2023-09-15: 306K2023-09-29: 444K2023-10-13: 415K2023-10-31: 423K2023-11-15: 377K2023-11-30: 402K2023-12-15: 400K2023-12-29: 264K2024-01-12: 224K2024-01-31: 242K2024-02-15: 213K2024-02-29: 249K2024-03-15: 262K2024-03-28: 197K2024-04-15: 214K2024-04-30: 230K2024-05-15: 204K2024-05-31: 339K2024-06-14: 376K2024-06-28: 369K2024-07-15: 390K2024-07-31: 309K2024-08-15: 1.7M2024-08-30: 2.4M2024-09-13: 2.2M
    the 13 Sep 2024 report24 earlier reportsnormal: 324K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  30. 20 Sep 2024Filings record

    Completed an acquisition or asset sale

  31. 12 Sep 2024Short interest and volume change

    had 2.4M shares sold short in the 30 Aug 2024 report, 9.1× the same report last year.

    Same report last year: 265K; its normal report is 308K.

    See the evidence
    This period
    2.4M (the 30 Aug 2024 report)
    Normal report (median of 24 earlier)
    308K
    Typical spread (median absolute deviation)
    80K
    How far from its usual level
    +17.8
    Same report last year
    265K
    History used
    2,436 days
    2023-08-31: 265K2023-09-15: 306K2023-09-29: 444K2023-10-13: 415K2023-10-31: 423K2023-11-15: 377K2023-11-30: 402K2023-12-15: 400K2023-12-29: 264K2024-01-12: 224K2024-01-31: 242K2024-02-15: 213K2024-02-29: 249K2024-03-15: 262K2024-03-28: 197K2024-04-15: 214K2024-04-30: 230K2024-05-15: 204K2024-05-31: 339K2024-06-14: 376K2024-06-28: 369K2024-07-15: 390K2024-07-31: 309K2024-08-15: 1.7M2024-08-30: 2.4M
    the 30 Aug 2024 report24 earlier reportsnormal: 308K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  32. 27 Aug 2024Short interest and volume change

    had 1.7M shares sold short in the 15 Aug 2024 report, 5.8× the same report last year.

    Same report last year: 286K; its normal report is 296K.

    See the evidence
    This period
    1.7M (the 15 Aug 2024 report)
    Normal report (median of 24 earlier)
    296K
    Typical spread (median absolute deviation)
    76K
    How far from its usual level
    +12.1
    Same report last year
    286K
    History used
    2,421 days
    2023-08-15: 286K2023-08-31: 265K2023-09-15: 306K2023-09-29: 444K2023-10-13: 415K2023-10-31: 423K2023-11-15: 377K2023-11-30: 402K2023-12-15: 400K2023-12-29: 264K2024-01-12: 224K2024-01-31: 242K2024-02-15: 213K2024-02-29: 249K2024-03-15: 262K2024-03-28: 197K2024-04-15: 214K2024-04-30: 230K2024-05-15: 204K2024-05-31: 339K2024-06-14: 376K2024-06-28: 369K2024-07-15: 390K2024-07-31: 309K2024-08-15: 1.7M
    the 15 Aug 2024 report24 earlier reportsnormal: 296K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  33. 13 Aug 2024Filings record

    A major agreement ended

  34. 23 May 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  35. 23 May 2024Filings record

    Director or officer change

  36. 23 Aug 2023Filings record

    Director or officer change

  37. 14 Aug 2023Institutional holdings change

    saw 39 13F filers open a new position in the quarter ended 30 Jun 2023, 3.2× the same quarter last year.

    Same quarter last year: 12; its normal quarter is 16.

    See the evidence
    This period
    39 (the quarter ended 30 Jun 2023)
    Normal quarter (median of 8 earlier)
    16
    Typical spread (median absolute deviation)
    2.5
    How far from its usual level
    +6.2
    Same quarter last year
    12
    History used
    3,560 days
    2021-06-30: 172021-09-30: 162021-12-31: 282022-03-31: 122022-06-30: 122022-09-30: 152022-12-31: 162023-03-31: 202023-06-30: 39
    the quarter ended 30 Jun 20238 earlier quartersnormal: 16

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  38. 25 May 2023Filings record

    Director or officer change

  39. 8 May 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  40. 8 May 2023Filings record

    Director or officer change

Showing the newest 40 of 88 entries; narrow the window or the kind of data to see older ones.

Not listed: 345 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001023024
Ticker
ANIP
Domain
anipharmaceuticals.com
Employer name
ANIP Acquisition Company, ANI Pharmaceuticals, Inc., NOVITIUM PHARMA LLC. (3 unverified)
Fein
20-0808920, 81-1305689 (2 unverified)
Hq location
NJ|PRINCETON|08540 (1 unverified)
Lobbying client
ani pharmaceuticals
Name
Alimera Sciences Europe Limited, Alimera Sciences, Inc, Alimera Sciences Ophthamologie GmbH, ANIP Acquisition Company and 9 more
  • DOL H-1B labor condition applications and PERM certifications57 data points9 Dec 2024 to 28 Sep 2026
  • Federal lobbying disclosures (LDA)4 records, 41 data points12 Feb 2018 to 30 Sep 2022
  • SEC Form 13F institutional holdings481 data points30 Jun 2013 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)202 records5 Jan 2016 to 5 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)993 data points31 Dec 2008 to 30 Sep 2026
  • SEC Form 4 insider transactions188 records, 588 data points9 Aug 2016 to 18 Nov 2026
  • FINRA short interest (twice monthly)636 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026